Pyxis Oncology
Pyxis Oncology is a Boston-based company developing next-generation therapeutics, including antibody-drug conjugates and monoclonal antibody immunotherapies, to target difficult-to-treat cancers.
Services
Pyxis Oncology develops next-generation therapeutics aimed at targeting difficult-to-treat cancers. The company's portfolio includes a variety of clinical assets, particularly focusing on antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies. These are used as monotherapies or in combination with other treatments. Pyxis Oncology leverages innovative immuno-oncology (IO) approaches designed to mobilize the body’s immune system to target and attack cancer cells.
Technology Platforms
Pyxis Oncology's technology platforms include the FACT and APXiMAB platforms. The FACT platform, developed by Pfizer, is designed to create next-generation ADCs with improved plasma stability, potency, and tumor permeability. The APXiMAB platform is known for producing diverse antibodies with high affinity, specificity, and stability through proprietary rabbit fusion cell lines and MLG humanization technologies. This platform has yielded several clinical candidates and one marketed product.
Products
Pyxis Oncology is currently investigating several clinical candidates. PYX-201, targeting tumor stroma, is in a Phase 1 dose-escalation trial for relapsed or refractory solid tumors and has received Orphan Drug Designation for pancreatic cancer by the FDA. PYX-106, a fully human monoclonal antibody targeting Siglec-15, is in a Phase 1 trial for advanced solid tumors. Other notable products include Sotigalimab (PYX-107) for soft tissue sarcoma and melanoma, PYX-203 for hematologic cancers, and APX801, an NK cell engager designed to activate natural killer cells.
Location
Pyxis Oncology is headquartered at 321 Harrison Avenue, 11th Floor, Suite 1, Boston, MA 02118. This location serves as the central hub for its research, development, and corporate activities.
Current Therapeutic Pipeline
The pipeline at Pyxis Oncology aims to address various challenging cancer types through innovative therapies. This includes PYX-102, which targets KLRG1 to activate an antitumor response and APX601, a TNFR2 antagonist aimed at reversing immune suppression in the tumor microenvironment. The strategic focus remains on developing therapeutics with the potential to significantly improve patient outcomes.